A single-center cohort study to identify uni- and multivariate associations between marker gene expression and clinico-pathological parameters for the detection of robust and novel prognostic tools in prostate cancer

1. To perform a large scale assessment of tissue hypoxia by pimonidazole and hypoxia marker gene expression in human prostate cancers
2. To characterize expression and hypoxia/HIF-responsiveness of myoglobin, cytoglobin, α-hemoglobin in prostate tumors and cell lines
3. To identify uni- and multivariate associations between marker gene expression and clinico-pathological parameters for the detection of robust and novel prognostic tools in prostate cancers

Inclusion criteria:

• Patients with biopsy-proven adenocarcinoma of the prostate who are to be treated with radical prostatectomy at the Department of Urology, University Hospital of Zurich
• Written informed consent

Exclusion criteria:

• Metastatic prostate cancer
• Contraindications to the class of investigational product under study, e.g. known hypersensitivity or allergy to the investigational product
• Severe heart or lung disease
• Severe liver or kidney dysfunction
• Severe stridor
• Distant metastases
• Concurrent treatment for other malignant disease
• Prior hormonal therapy or radiotherapy

Patients with biopsy-proven adenocarcinoma of the prostate who are to be treated with radical prostatectomy at the Department of Urology, University Hospital of Zurich